Planning and Evaluation

规划与评估

• 批准号: 8208804
• 负责人: THEODORE G KRONTIRIS
• 金额: $ 2.68万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8208804
• 关键词: Advisory Committees; Animals; Basic Science; Biopolymers; Cancer Center; Cancer Center Support Grant; Chemistry; Cities; Clinical; Clinical Research; Clinical Trials; Communities; Consultations; Correlative Study; Decision Making; Development; Development Plans; Disease; Ensure; Evaluation; Evolution; Funding; Future; Goals; Grant; Hospitals; Image; Immunobiology; Immunotherapeutic agent; Laboratories; Leadership; Medical center; Minority; Outcome; Parents; Play; Policies; Population Sciences; Positioning Attribute; Process; Productivity; Program Development; Recruitment Activity; Research; Research Institute; Resources; Role; Scientist; Seeds; Services; Strategic Planning; Surveys; authority; base; cancer prevention; cancer research center director; functional genomics; high throughput screening; meetings; member; programs

The COHCCC Director has a wide array of advisory inputs to assist in planning for the Center's future and evaluating the outcomes of Center program and policy implementation. The most important of these is the day-to-day decision-making body, the Cancer Center Leadership Committee. This group consists of the traditional senior leaders of the Center (Deputy and Associate Directors), as well as the Program Co-Leaders and several other key senior members of the Center. All plans either originate in or pass through this group. In recent years, our External Advisory Committee has played an ever larger role in reviewing our plans and advising on our course of action; the EAC is also particularly important in its evaluative function. In this program cycle, the Director has established two new committees of CC leaders to advise on the overhauling of the Center's clinical trials apparatus and in developing new disease-based research programs. These are, respectively, the Clinical Research Governance Board and the Cancer Center Task Force for Disease Program Development. To assist in Institutional strategic planning, all senior scientific, clinical, and administrative leaders form the Clinical and Scientific Executive Team. City of Hope Corporate Boards of Directors (for the Parent Corporation, as well as for the Beckman Research Institute [BRI] and National Medical Center [NMC]) provide a lay perspective to the Director on many issues and, ultimately, approve the Cancer Center's strategic directions. Finally, for consultation relating to academic issues or clinical programs, respectively, the Director meets regularly with the BRI Council of Chairs and the NMC Council of Chairs. The Cancer Center Minority Task Force advises on interlocking initiaves for community engagement in CCARE. In the upcoming program period, there are several major initiatives for which our planning processes and advisory bodies are fully engaged. These include: (1) full implementation of the three developing cores; (2) full implementation of the CCARE initiative; (3) the evolution of one or several clinical programs into Cancer Center disease-based research programs; and (4) full implementation of our long-range plan for the development of cancer prevention and population science research.

COHCCC董事有各种各样的咨询意见，可以帮助计划中心的未来和 评估中心计划和政策实施的结果。其中最重要的是 癌症中心领导委员会的日常决策机构。这个小组包括 该中心的传统高级领导人（副董事和副董事）以及计划共同领导者 以及该中心的其他几个主要高级成员。所有计划都源于该小组，要么通过该小组。 近年来，我们的外部咨询委员会在审查我们的计划中发挥了更大的作用 并为我们的行动方案提供建议； EAC在其评估功能中也尤其重要。在这个 计划周期，董事已经成立了两个新的CC领导委员会，以进行大修 该中心的临床试验设备以及开发新的基于疾病的研究计划。这些 分别是临床研究治理委员会和癌症中心工作队 疾病计划的发展。为了协助机构战略规划，所有高级科学，临床， 行政领导人组成了临床和科学执行团队。希望城市公司 董事会（用于母公司，以及贝克曼研究所[BRI]和 国家医疗中心[NMC]）在许多问题上为董事提供了一个言论。 批准癌症中心的战略方向。最后，用于与学术问题有关的咨询或 临床计划分别定期与BRI椅子和NMC会面 主席理事会。癌症中心少数族裔特遣部队为互锁的启动提供建议 社区参与CCARE。在即将到来的计划期间，有几项主要举措 我们的计划过程和咨询机构完全参与其中。其中包括：（1）完整实施 在三个发展中心的核心中； （2）全面执行CCARE倡议； （3）一个或 基于癌症中心的研究计划的几个临床计划； （4）完整实施 我们的远程预防和人口科学研究的远程计划。